Sugi Predict

Sugi Predict / Compounds / SCHEMBL360667

SCHEMBL360667

SCHEMBL360667

CCOC(=O)C(C#N)c1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.51
▸ KMT2A Q03164 4/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ GAA P10253 2/20 0.51
▸ LMNA P02545 5/20 0.47
▸ ALDH1A1 P00352 5/20 0.47
▸ TDP1 Q9NUW8 2/20 0.47
▸ ALPG P10696 2/20 0.45
▸ MAPT P10636 4/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ THRB P10828 1/20 0.41
▸ ALOX12 P18054 1/20 0.41
▸ HPGD P15428 3/20 0.41
▸ USP2 O75604 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ CASP3 P42574 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17466005 0.92 MEN1 (0.58) SMN1; SMN2KMT2AMEN1GAALMNA
SCHEMBL6289274 0.87 SMN1; SMN2 (0.54) SMN1; SMN2KMT2AMEN1GAALMNA
SCHEMBL9586863 0.86 MAPT (0.47) SMN1; SMN2KMT2AMEN1GAALMNA
SCHEMBL5081149 0.84 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AMEN1GAALMNA
SCHEMBL13700788 0.84 KMT2A (0.51) SMN1; SMN2KMT2AMEN1GAALMNA
SCHEMBL15475549 0.84 KMT2A (0.48) SMN1; SMN2KMT2AMEN1GAALMNA
SCHEMBL30771326 0.84 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AMEN1GAALMNA
SCHEMBL31724117 0.83 ALDH1A1 (0.47) SMN1; SMN2KMT2AMEN1GAALMNA
SCHEMBL502194 0.83 SMN1; SMN2 (0.61) SMN1; SMN2KMT2AMEN1GAALMNA
SCHEMBL19492500 0.83 GAA (0.48) SMN1; SMN2KMT2AMEN1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4633734-A1 COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING Wavebreak Therapeutics, LLC (US) 2025-10-22 — — EP disclosed
WO-2024129881-A1 COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING WAVEBREAK THERAPEUTICS LIMITED (US) 2024-06-20 — — WO disclosed
EP-3229801-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2020-04-01 — — EP disclosed
US-10385012-B2 Thioamides and amides for controlling animal pests BASF SE (DE) 2019-08-20 — — US disclosed
US-10385012-B2 Thioamides and amides for controlling animal pests BASF SE (DE) 2019-08-20 — — US disclosed
US-10189819-B2 Factor IXa inhibitors MERCK SHARP & DOHME, CORP. (US) 2019-01-29 — — US disclosed
US-20180030036-A1 Factor IXa Inhibitors MERCK SHARP & DOHME CORP. (US) 2018-02-01 — — US disclosed
EP-3229801-A1 FACTOR IXA INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-10-18 — — EP disclosed
EP-2668168-B1 COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2017-03-01 — — EP disclosed
EP-2668168-B1 COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2017-03-01 — — EP disclosed
US-20120028994-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY 2012-02-02 — — US disclosed
WO-2012009309-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2012-01-19 — — WO disclosed
US-20110245223-A1 HETEROCYCLIC COMPOUNDS JAPAN TOBACCO INC. (JP) 2011-10-06 — — US disclosed
US-20110212937-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY 2011-09-01 — — US disclosed
US-20110212937-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY 2011-09-01 — — US disclosed
WO-2011014535-A1 COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-03 — — WO disclosed
US-20100010219-A1 METHOD FOR PRODUCING PYRROLIDINE COMPOUND JAPAN TOBACCO INC. (JP) 2010-01-14 — — US disclosed
EP-2103603-A1 METHOD FOR PRODUCING PYRROLIDINE COMPOUND Japan Tobacco Inc. (JP) 2009-09-23 — — EP disclosed
EP-1889842-A1 HETEROCYCLIC COMPOUND Japan Tobacco, Inc. (JP) 2008-02-20 — — EP disclosed
US-20070072908-A1 Heterocyclic compounds JAPAN TOBACCO INC. (JP) 2007-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245223-A1 HETEROCYCLIC COMPOUNDS HSD11B1, HSD11B2, CYP11B1 SMN1; SMN2 4450/4885KMT2A 1820/4885MEN1 935/4885
US-20110212937-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION APP, BACE1, IAPP SMN1; SMN2 760/4885KMT2A 4529/4885MEN1 3911/4885
US-10385012-B2 Thioamides and amides for controlling animal pests TST, TMT1A, ACHE SMN1; SMN2 2267/4885KMT2A 171/4885MEN1 3313/4885
US-20120028994-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION APP, BACE1, IAPP SMN1; SMN2 760/4885KMT2A 4529/4885MEN1 3911/4885
US-20070072908-A1 Heterocyclic compounds HSD11B1, HSD11B2, CYP11B1 SMN1; SMN2 4450/4885KMT2A 1820/4885MEN1 935/4885
US-20100010219-A1 METHOD FOR PRODUCING PYRROLIDINE COMPOUND HSD11B1, HSD11B2, HSD17B11 SMN1; SMN2 3035/4885KMT2A 3033/4885MEN1 1832/4885
US-20180030036-A1 Factor IXa Inhibitors F9, TFPI, F12 SMN1; SMN2 3148/4885KMT2A 4286/4885MEN1 2982/4885
US-10189819-B2 Factor IXa inhibitors F9, TFPI, F12 SMN1; SMN2 3148/4885KMT2A 4286/4885MEN1 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.